Michael R. Liebowitz
#113,050
Most Influential Person Now
Michael R. Liebowitz's AcademicInfluence.com Rankings
Download Badge
Biology
Why Is Michael R. Liebowitz Influential?
(Suggest an Edit or Addition)Michael R. Liebowitz's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Social phobia. Comorbidity and morbidity in an epidemiologic sample. (1992) (1156)
- Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. (2007) (818)
- Psychometric properties of the Liebowitz Social Anxiety Scale (1999) (812)
- The Liebowitz Social Anxiety Scale: a comparison of the psychometric properties of self-report and clinician-administered formats (2001) (772)
- Assessment of anxiety in social interaction and being observed by others: The social interaction anxiety scale and the Social Phobia Scale (1992) (686)
- Social phobia. Review of a neglected anxiety disorder. (1985) (564)
- Functional impairment in social phobia. (1994) (517)
- Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. (1998) (503)
- Social phobia. (1987) (480)
- Empirical validation and psychometric evaluation of the Brief Fear of Negative Evaluation Scale in patients with social anxiety disorder. (2005) (473)
- Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. (1992) (427)
- Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale. (2002) (380)
- Lactate provocation of panic attacks. II. Biochemical and physiological findings. (1985) (374)
- Lactate provocation of panic attacks. I. Clinical and behavioral findings. (1984) (355)
- A neuroanatomical hypothesis for panic disorder. (1989) (354)
- Ventilatory physiology of patients with panic disorder. (1988) (351)
- Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. (1998) (351)
- Screening for social anxiety disorder with the self‐report version of the Liebowitz Social Anxiety Scale (2009) (342)
- Response to hyperventilation in a group of patients with panic disorder. (1984) (339)
- Low dopamine D(2) receptor binding potential in social phobia. (2000) (319)
- Antidepressant specificity in atypical depression. (1988) (316)
- The empirical basis of generalized anxiety disorder. (1994) (296)
- Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. (1991) (294)
- Disability and quality of life in pure and comorbid social phobia. Findings from a controlled study (1999) (293)
- Pharmacotherapy of Social Phobia (1992) (277)
- Generalized social phobia. Reliability and validity. (1995) (268)
- Evaluation of the Clinical Global Impression Scale among individuals with social anxiety disorder (2003) (263)
- Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. (1992) (263)
- Attachment in individuals with social anxiety disorder: the relationship among adult attachment styles, social anxiety, and depression. (2001) (255)
- The OCI-R: validation of the subscales in a clinical sample. (2007) (249)
- A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. (2008) (239)
- Quality of life and functional impairment in obsessive–compulsive disorder: a comparison of patients with and without comorbidity, patients in remission, and healthy controls (2009) (226)
- Signs of central nervous system dysfunction in obsessive-compulsive disorder. (1990) (225)
- Phenelzine v imipramine in atypical depression. A preliminary report. (1984) (225)
- Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. (1995) (225)
- Measurement of lactate-induced panic and anxiety (1987) (219)
- An Open Trial of Fluoxetine in the Treatment of Panic Attacks (1987) (216)
- The issue of subtypes in the diagnosis of social phobia (1993) (212)
- Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) (2019) (206)
- Cognitive‐behavioral group therapy versus phenelzine in social phobia: Long term outcome (1999) (204)
- Review and critique of the new DSM-IV diagnosis of acute stress disorder. (1999) (201)
- Maternal mental representations of the child in an inner-city clinical sample: Violence-related posttraumatic stress and reflective functioning (2005) (188)
- A direct interview family study of social phobia. (1993) (184)
- An investigation of gender differences in social phobia. (1998) (184)
- Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. (2013) (180)
- The factor structure and screening utility of the Social Interaction Anxiety Scale. (2006) (175)
- Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. (1988) (174)
- Anger experience and expression in social anxiety disorder: Pretreatment profile and predictors of attrition and response to cognitive-behavioral treatment (2003) (174)
- Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias. (1992) (171)
- Neurobiology of impulsivity and the impulse control disorders. (1993) (170)
- Response versus remission in obsessive-compulsive disorder. (2006) (169)
- More reasons to be straightforward: findings and norms for two scales relevant to social anxiety. (2011) (159)
- Discontinuation of alprazolam treatment in panic patients. (1987) (158)
- The social anxiety spectrum. (2002) (156)
- Pharmacological treatment of social anxiety disorder: A meta‐analysis (2003) (155)
- Moclobemide in social phobia: a controlled dose-response trial. (1997) (153)
- Responses of “generalized” and “discrete” social phobics during public speaking (1993) (151)
- Distorted Maternal Mental Representations and Atypical Behavior in a Clinical Sample of Violence-Exposed Mothers and Their Toddlers (2008) (150)
- A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. (2010) (148)
- Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. (2005) (148)
- Atomoxetine treatment in adults with attention‐deficit/hyperactivity disorder and comorbid social anxiety disorder (2009) (148)
- Treatment of body-dysmorphic disorder with serotonin reuptake blockers. (1989) (147)
- Specificity of neuropsychological impairment in obsessive-compulsive disorder: a comparison with social phobic and normal control subjects. (1996) (146)
- Reliability of anxiety assessment. I. Diagnostic agreement. (1989) (146)
- Gender differences in social anxiety disorder: results from the national epidemiologic sample on alcohol and related conditions. (2012) (144)
- High-dose carbon dioxide challenge test in anxiety disorder patients (1990) (141)
- The relationship of social phobia subtypes and avoidant personality disorder. (1991) (141)
- An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. (1998) (140)
- Metabolism of (‐) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit (1982) (140)
- Factor structure of social fears: The Liebowitz Social Anxiety Scale. (1999) (140)
- Traumatized mothers can change their minds about their toddlers: Understanding how a novel use of videofeedback supports positive change of maternal attributions. (2006) (139)
- SOCIAL ANXIETY DISORDER IN DSM‐5 (2014) (137)
- Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings. (1988) (137)
- Quantitative electroencephalographic subtyping of obsessive-compulsive disorder (1993) (136)
- Diagnostic and substance specificity of carbon-dioxide-induced panic. (1993) (136)
- Fear and avoidance of eye contact in social anxiety disorder. (2011) (136)
- Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. (2002) (136)
- Tranylcypromine in social phobia. (1988) (136)
- The Liebowitz social anxiety scale for children and adolescents: an initial psychometric investigation. (2003) (135)
- The psychometric properties of the Interpersonal Sensitivity Measure in social anxiety disorder. (2002) (132)
- Placebo-controlled trial of moclobemide in social phobia (1998) (131)
- Childhood separation anxiety disorder in patients with adult anxiety disorders. (1994) (130)
- Fluoxetine in panic disorder. (1990) (129)
- Situational domains of social phobia (1992) (128)
- National Trends in Ethnic Disparities in Mental Health Care (2007) (128)
- Relations of the factors of the tripartite model of anxiety and depression to types of social anxiety. (2006) (126)
- Alcohol abuse in social phobia (1989) (126)
- Personality features of patients with primary affective disorder (1979) (122)
- Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chloro-phenylpiperazine in obsessive-compulsive disorder (1991) (121)
- Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial (2007) (121)
- Specificity of lactate infusions in social phobia versus panic disorders. (1985) (119)
- Post‐treatment effects of exposure therapy and clomipramine in obsessive–compulsive disorder (2004) (119)
- A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. (2002) (114)
- Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry. (2002) (114)
- Phenelzine in social phobia. (1986) (107)
- Neuropsychology of obsessive compulsive disorder: Preliminary findings. (1994) (105)
- Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol. (1988) (105)
- CO2 challenge of patients with panic disorder. (1987) (104)
- Cognitive Behavioral Group Therapy vs Phenelzine Therapy for Social Phobia (1998) (103)
- Familial transmission of simple phobias and fears. A preliminary report. (1990) (103)
- Imipramine in the treatment of social phobia. (1998) (102)
- Item-by-item factor analysis of the Yale-Brown Obsessive Compulsive Scale Symptom Checklist. (2003) (102)
- Efficacy of desipramine in depressed outpatients. Response according to research diagnosis criteria diagnoses and severity of illness. (1983) (102)
- Comparative Phenomenology of Ataques de Nervios, Panic Attacks, and Panic Disorder (2002) (101)
- Treatment of obsessive—compulsive disorder with fluvoxamine: a multicentre, double‐blind, placebo‐controlled trial (1996) (101)
- Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. (1998) (100)
- Myth of the pure obsessional type in obsessive–compulsive disorder (2011) (98)
- Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. (2003) (98)
- Interrelationship of hysteroid dysphoria and borderline personality disorder. (1981) (98)
- A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. (2005) (97)
- Are there reliable neuropsychological deficits in obsessive-compulsive disorder? (2006) (95)
- Cortisol and sodium lactate-induced panic. (1989) (94)
- Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [11C]McN 5652 (2003) (91)
- Striatal dopamine D2 receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings (2008) (90)
- Plasma cortisol concentrations preceding lactate-induced panic. Psychological, biochemical, and physiological correlates. (1998) (90)
- Pituitary adrenocortical unresponsiveness in lactate-induced panic (1987) (90)
- Psychometric properties of disability measures among patients with social anxiety disorder. (2004) (88)
- Possible mechanisms for lactate's induction of panic. (1986) (86)
- l-Deprenyl in atypical depressives. (1984) (85)
- Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder (2009) (84)
- Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. (2008) (84)
- The evidence-based pharmacotherapy of social anxiety disorder. (2013) (84)
- Effect of Acute ß-Adrenergic Blockade on Lactate-Induced Panic (1983) (83)
- Disability and quality of life in pure and comorbid social phobia – Findings from a controlled study (1999) (83)
- Childhood maltreatment and social anxiety disorder: implications for symptom severity and response to pharmacotherapy (2012) (83)
- Brain event-related potential correlates of overfocused attention in obsessive-compulsive disorder. (1994) (81)
- A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults (2007) (81)
- Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo‐controlled trial (2010) (80)
- Ataque de nervios and panic disorder. (1994) (79)
- Memory bias does not generalize across anxiety disorders. (1995) (75)
- Hypochondriasis and obsessive compulsive disorder: overlaps in diagnosis and treatment. (1991) (75)
- The chemistry of love (1983) (75)
- The experience of disability and quality of life in social anxiety disorder (2003) (75)
- Treatment of Social Phobia with Atenolol (1985) (74)
- A randomized trial of interpersonal therapy versus supportive therapy for social anxiety disorder (2008) (72)
- A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. (2007) (72)
- Generalizability of clinical trial results for major depression to community samples: results from the National Epidemiologic Survey on Alcohol and Related Conditions. (2008) (71)
- Features of the offensive subtype of Taijin‐Kyofu‐Sho in US and Korean patients with DSM‐IV social anxiety disorder (2008) (71)
- Fluoxetine for hypochondriacal patients without major depression. (1993) (70)
- The evidence-based pharmacological treatment of social anxiety disorder. (2003) (70)
- Noradrenergic function in obsessive-compulsive disorder: Behavioral and neuroendocrine responses to clonidine and comparison to healthy controls (1991) (69)
- Obsessive compulsive personality disorder as a predictor of exposure and ritual prevention outcome for obsessive compulsive disorder. (2011) (68)
- Effects of naloxone on patients with panic attacks. (1984) (67)
- Delineating the boundaries of social phobia: Its relationship to panic disorder and agoraphobia (1990) (67)
- Social phobia or social anxiety disorder: what's in a name? (2000) (66)
- Childhood trauma and dissociative symptoms in panic disorder. (2000) (66)
- Neuropsychiatric impairment in impulsive personality disorders (1993) (66)
- A controlled study of cognitive deficits in children with chronic Lyme disease. (2001) (65)
- Update on the diagnosis and treatment of social anxiety disorder. (1999) (65)
- Alprazolam in the treatment of panic disorders. (1986) (63)
- A 2‐year study of sertraline in the treatment of obsessive‐compulsive disorder (1997) (62)
- A comparison of sodium bicarbonate and sodium lactate infusion in the induction of panic attacks. (1989) (62)
- Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. (2014) (62)
- Panic attacks during placebo procedures in the laboratory. Physiology and symptomatology. (1993) (61)
- Blood gas changes and hypophosphatemia in lactate-induced panic. (1986) (60)
- Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders (1990) (60)
- Lactate infusions in obsessive-compulsive disorder. (1985) (59)
- The impact of symptom dimensions on outcome for exposure and ritual prevention therapy in obsessive-compulsive disorder. (2014) (59)
- Buspirone in social phobia. (1993) (59)
- Fluoxetine in social phobia. (1992) (58)
- Is borderline a distinct entity? (1979) (58)
- An empirical approach to subtype identification in individuals with social phobia (2000) (58)
- The pharmacotherapy of hypochondriasis. (1996) (57)
- Treatment outcome validation of DSM-III depressive subtypes. Clinical usefulness in outpatients with mild to moderate depression. (1985) (57)
- Treatment of Depersonalization with Serotonin: Reuptake Blockers (1990) (57)
- Psychopharmacological treatment of social phobia. (1985) (56)
- Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. (1990) (56)
- Psychiatric manifestations of Lyme borreliosis. (1993) (56)
- Psychobiological dysregulation in violence-exposed mothers: salivary cortisol of mothers with very young children pre- and post-separation stress. (2004) (55)
- Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder* (2008) (54)
- Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. (1999) (54)
- Moderators and predictors of response to cognitive-behavioral therapy augmentation of pharmacotherapy in obsessive–compulsive disorder (2010) (54)
- Memory bias in panic disorder: An investigation of the cognitive avoidance hypothesis (1991) (53)
- The tyramine challenge test as a marker for melancholia. (1984) (53)
- Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial. (1989) (52)
- Pharmacotherapy of social anxiety disorder (2002) (52)
- Tricyclic therapy of the DSM-III anxiety disorders: a review with implications for further research. (1988) (51)
- Subtypes of Ataques de Nervios: The Influence of Coexisting Psychiatric Diagnosis (1998) (51)
- Body dysmorphic disorder. Diagnostic issues and related disorders. (1992) (50)
- Psychopharmacologic treatment of child and adolescent obsessive compulsive disorder. (1992) (50)
- Citalopram treatment of social anxiety disorder with comorbid major depression (2003) (49)
- Neuropsychiatric and neuropsychological findings in conduct disorder and attention-deficit hyperactivity disorder. (1994) (48)
- The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. (1984) (48)
- Epinephrine infusions in patients with social phobia. (1988) (47)
- Reliability of anxiety assessment. II. Symptom agreement. (1989) (47)
- A pilot study of noradrenergic and HPA axis functioning in PTSD vs. panic disorder (2002) (47)
- Standard criteria for relapse are needed in obsessive–compulsive disorder (2005) (46)
- Reaction time to threat stimuli in panic disorder and social phobia. (1992) (46)
- A Double-Masked, Placebo-Controlled Study of Fluoxetine for Hypochondriasis (2008) (46)
- The offensive subtype of Taijin-kyofu-sho in New York City: the phenomenology and treatment of a social anxiety disorder. (1996) (46)
- The mitral valve prolapse—panic disorder connection. (1988) (45)
- Clonidine and clomipramine in obsessive-compulsive disorder. (1988) (45)
- Perceptions of control in panic disorder and social phobia (1992) (44)
- Limb compression and renal impairment (crush syndrome) complicating narcotic overdose. (1971) (44)
- Evaluation of the Psychometric Properties of Two Short Forms of the Social Interaction Anxiety Scale and the Social Phobia Scale (2014) (44)
- Relation of marital status to social phobia severity (1999) (43)
- Ataque de Nervios and History of Childhood Trauma (2000) (43)
- The neuropsychiatric manifestations of Lyme borreliosis (2005) (43)
- Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. (1995) (43)
- Anxiety and Depression: Discrete Diagnostic Entities? (1990) (43)
- Hypersensitivity to carbon dioxide in panic disorder. (1989) (42)
- Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. (2008) (42)
- A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder (2013) (42)
- Normalization of venous pH, pCO2, and bicarbonate levels after blockade of panic attacks (1985) (40)
- Sodium D-lactate infusion of panic disorder patients. (1990) (39)
- Arterial blood gas changes in panic disorder and lactate- induced panic (1989) (39)
- Phenelzine and atenolol in social phobia. (1990) (39)
- A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder. (2009) (38)
- Phenylacetic acid excretion in schizophrenia and depression: the origins of PAA in man. (1984) (38)
- Treatment outcome of obsessive compulsive disorder with comorbid social phobia. (1992) (38)
- The pharmacotherapy of moral or religious scrupulosity. (1990) (37)
- Monoamine Oxidase Inhibitors in Bipolar Endogenous Depressives (1981) (37)
- Vulnerability to sodium lactate in panic disorder patients given cognitive-behavioral therapy. (1991) (35)
- Paroxetine/bupropion combination treatment for refractory depression. (1996) (35)
- The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study (2020) (35)
- Lactate provocation of panic attacks in depressed outpatients (1988) (35)
- MAOIs: Impact on social behavior (1987) (34)
- An open trial of fluvoxamine for hypochondriasis. (2003) (34)
- Fluoxetine for adolescents with obsessive-compulsive disorder. (1990) (34)
- Open trial of intravenous clomipramine in five treatment-refractory patients with obsessive-compulsive disorder. (1992) (34)
- Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder. (2013) (33)
- Comparison of clomipramine, alprazolam and placebo in the treatment of obsessive—compulsive disorder (1992) (33)
- Overview of panic and social anxiety disorders. (2004) (33)
- Neurologic Soft Signs in Obsessive-Compulsive Disorder-Reply (1991) (32)
- Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. (2010) (32)
- Hyperventilation occurs during lactate-induced panic (1988) (32)
- Late-stage neuropsychiatric Lyme borreliosis. Differential diagnosis and treatment. (1995) (32)
- Chronic Catheterization of Coronary Artery (1961) (32)
- A controlled study of the effects of antidepressants on sexual function. (1985) (31)
- Factor Structure of the Liebowitz Social Anxiety Scale for Children and Adolescents (2006) (31)
- Hysteroid dysphoria. (1982) (31)
- Panic disorder as a chronic illness. (1997) (31)
- Lactate vulnerability of remitted panic patients (1985) (31)
- Treatment of social phobia with drugs other than benzodiazepines. (1991) (31)
- Fluoxetine and extrapyramidal symptoms in CNS lupus. (1991) (30)
- Physical disability and social phobia. (1994) (30)
- Timing of neuroendocrine responses and effect of m-CPP and fenfluramine plasma levels in OCD (1993) (30)
- Depression with anxiety and atypical depression. (1993) (30)
- Biochemical effects of l-deprenyl in atypical depressives (1985) (29)
- The role of the kidney in the homeostatic adjustments of congestive heart failure. (1959) (29)
- Conceptual and methodological issues in studies of obsessive-compulsive and Tourette's disorders. (1989) (28)
- Possible respiratory abnormalities in panic disorder. (1986) (28)
- Imipramine in the treatment of panic disorder and its complications. (1985) (28)
- Ziprasidone monotherapy in bipolar II depression: an open trial. (2009) (28)
- Cognitive‐Behavior Therapy for Panic Disorder Delivered by Psychopharmacologically Oriented Clinicians (1991) (28)
- The Social Interaction Phobia Scale: Continued support for the psychometric validity of the SIPS using clinical and non-clinical samples. (2015) (27)
- Limb compression and renal impairment (crush syndrome) following narcotic and sedative overdose. (1972) (27)
- Dr. Hollander and Associates Reply (1989) (27)
- Noradrenergic function in panic disorder effects of intravenous clonidine pretreatment on lactate induced panic (1992) (27)
- Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder. (2015) (27)
- Pathological Gambling: Addiction or Obsession? (2002) (26)
- Ondansetron in the treatment of panic disorder. (1996) (26)
- Phenelzine versus imipramine in atypical depression: a preliminary report (1985) (26)
- Low dose selegiline (L‐Deprenyl) in social phobia (1998) (26)
- Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder (2017) (26)
- Symptom provocation alters behavioral ratings and brain electrical activity in obsessive–compulsive disorder: a preliminary study (2000) (26)
- Personality disorders in hypochondriasis: prevalence and comparison with two anxiety disorders. (2012) (25)
- Defining the boundaries of atypical depression. (1984) (25)
- Efficacy of desipramine in endogenomorphically depressed patients. (1980) (25)
- Perception matters for clinical perfectionism and social anxiety. (2015) (25)
- A pilot follow-up study of childhood soft signs and the development of adult psychopathology. (1991) (24)
- Anxiety and panic attacks in the medically ill. (1981) (24)
- Cardiac left ventricular hypertrophy and chamber dilatation in panic disorder patients: Implications for idiopathic dilated cardiomyopathy (1990) (24)
- The appraisal of social concerns scale: psychometric validation with a clinical sample of patients with social anxiety disorder. (2006) (23)
- Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. (2010) (22)
- An objective marker of lactate-induced panic (1987) (22)
- Phenelzine‐Induced Pyridoxine Deficiency (1984) (22)
- Social anxiety and functional impairment in patients seeking surgical evaluation for hyperhidrosis. (2012) (22)
- Hypoglycemia and panic attacks. (1984) (21)
- Effects of fenfluramine on plasma HVA in OCD (1992) (20)
- Pharmacotherapy of four men with paruresis. (1990) (20)
- Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder. (2014) (20)
- Platelet monoamine oxidase activity in patients with panic disorder (1985) (20)
- Neurological soft signs in social phobia (1996) (20)
- Mixed anxiety and depression: should it be included in DSM-IV? (1993) (20)
- Statistical choices can affect inferences about treatment efficacy: a case study from obsessive-compulsive disorder research. (2008) (19)
- Discriminating between generalized anxiety disorder and anxiety disorder not otherwise specified in a Hispanic population: Is it only a matter of worry? (1997) (18)
- A comparison of phobic subtypes within panic disorder (1991) (18)
- Prolactin and sodium lactate-induced panic (1989) (18)
- Social phobia: anxiety disorder comorbidity. (1994) (17)
- The structure of vulnerabilities for social anxiety disorder (2017) (17)
- Depression with anxiety and atypical depression. Discussion (1993) (17)
- Body-dysmorphic disorder (I: Reply) (1990) (17)
- A Pharmacotherapy Algorithm in the Treatment of Posttraumatic Stress Disorder (1996) (16)
- Striatal IMP-SPECT decrease in obsessive-compulsive disorder, normalized by pharmacotherapy. (1989) (15)
- Fenfluramine, cortisol, and anxiety (1990) (15)
- Obsessive compulsive disorder, depression, and fluoxetine. (1991) (15)
- Differential diagnosis and treatment of panic attacks and phobic states. (1981) (15)
- Social phobia: Biology and pharmacology (1989) (15)
- Dissociative experiences scale. (1992) (14)
- Response of obsessive-compulsive disorder and trichotillomania to serotonin reuptake blockers. (1992) (14)
- Biological Aspects of Obsessive Compulsive Disorder (1989) (14)
- Antidepressant-induced rapid cycling: six case reports. (1993) (14)
- Globus hystericus and panic attacks. (1987) (14)
- The lactate infusion model. (1985) (14)
- Social anxiety disorder: Recent findings in the areas of epidemiology, etiology, and treatment (2001) (14)
- Integrating Neurobiology and Psychopathology into Evidence-Based Treatment of Social Anxiety Disorder (2005) (13)
- Sodium lactate infusion, panic attacks, and ionized calcium. (1984) (13)
- Detachment and generalized social phobia. (2001) (13)
- The Safety and Tolerability Profile of Vilazodone, A Novel Antidepressant for the Treatment of Major Depressive Disorder. (2011) (13)
- A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Vilazodone in Generalized Social Anxiety Disorder. (2015) (13)
- Antidepressants in Panic Disorders (1989) (12)
- Do panic disorder patients indiscriminately endorse somatic complaints? (1989) (12)
- Hypochondriasis: Treatment Strategies (1993) (12)
- Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia. (1993) (12)
- An open clinical trial of mianserin. (1981) (12)
- Pharmacotherapy of social phobia. (1987) (12)
- Liebowitz Social Phobia Scale (2013) (12)
- Biological accompaniments of lactate-induced panic. (1984) (12)
- Adverse events in PTSD patients taking fluoxetine. (1995) (11)
- Augmentation of antiobsessional treatment with fenfluramine. (1988) (11)
- Effect of panic attacks on the treatment of atypical depressives. (1985) (11)
- Effects of intravenous diazepam pretreatment on lactate-induced panic (1995) (11)
- Use of Psychotropic Medications for Patients With Office Visits Who Receive a Diagnosis of Panic Disorder (2004) (11)
- Reversible monoamine oxidase-A inhibitors in social phobia. (1993) (10)
- Phenelzine and delusions of parasitosis: a case report. (1978) (10)
- Mianserin versus amitriptyline for depression: a double-blind 6-week trial. (1984) (10)
- Assessing the Straightforwardly-Worded Brief Fear of Negative Evaluation Scale for Differential Item Functioning Across Gender and Ethnicity (2015) (9)
- Social phobia and stuttering. (1997) (9)
- Long-term follow-up study of patients with refractory obsessive-compulsive disorder. (2008) (9)
- Issues in the design of trials for the evaluation of psychosocial treatments for social phobia (1996) (9)
- A Medication Approach (1987) (9)
- Psychopharmacologic validation of atypical depression. (1984) (9)
- A pilot study of biological predictors of treatment outcome in obsessive-compulsive disorder (1993) (9)
- Sodium lactate response and familial risk for panic disorder. (1995) (9)
- More on Self Mutilation and Obsessive Compulsive Disorder (1988) (9)
- Effect of as‐needed use of intranasal PH94B on social and performance anxiety in individuals with social anxiety disorder (2016) (9)
- Neuroendocrine predictors of response to intravenous clomipramine therapy for refractory obsessive–compulsive disorder (2001) (9)
- Adinazolam Sustained‐Release Treatment of Panic Disorder: A Double‐Blind Study (1994) (9)
- Lactate-induced anxiety (1989) (8)
- Delineating Social Phobia (1987) (8)
- Potential mechanisms for sodium lactate's induction of panic (1990) (8)
- Treatment of stuttering with phenelzine. (1993) (8)
- Clinical presentation and pharmacotherapy response in social anxiety disorder: The effect of etiological beliefs (2015) (8)
- Effect of acute beta-adrenergic blockade on lactate-induced panic. (1983) (8)
- Pharmacological dissection of panic and depersonalization. (1989) (8)
- Effects of clonidine on alprazolam discontinuation in panic patients: a pilot study. (1988) (8)
- Cortisol response to dextroamphetamine stimulation in depressed outpatients (1984) (8)
- The effect of acetazolamide on ventilation in panic disorder patients. (1993) (8)
- Commentary on the Criteria for Self-Defeating Personality Disorder (1987) (7)
- Managing dissociative symptoms following the use of esketamine nasal spray: a case report (2020) (7)
- Neuroendocrine predictors of response to intravenous clomipramine therapy for refractory obsessive-compulsive disorder. (2001) (7)
- VERSION OF THE LIEBOWITZ SOCIAL ANXIETY SCALE (2008) (7)
- Pharmacotherapy for social anxiety disorder: Interpersonal predictors of outcome and the mediating role of the working alliance. (2017) (7)
- Neuroendocrine sensitivity in obsessive-compulsive disorder (1989) (6)
- Combining Pharmacotherapy and Cognitive-Behavioral Therapy in the Treatment of OCD (2005) (6)
- REVERSIBLE MAO INHIBITORS IN SOCIAL PHOBIA BULIMIA, AND OTHER DISORDERS (1992) (6)
- Social anxiety disorder: Current perspectives on diagnosis and treatment (2005) (6)
- Alpidem in the treatment of panic disorder. (1993) (6)
- Anxiety Disorders and Obsessive Compulsive Disorder (1998) (6)
- NEUROLOGIC SOFT SIGNS IN OBSESSIVE-COMPULSIVE DISORDER. AUTHOR'S REPLY (1991) (6)
- Antipanic drug effects during lactate infusion in lactate-refractory panic patients (1987) (6)
- General principles in the pharmacotherapy of antidepressant-induced rapid cycling: a case series. (1997) (6)
- Antidepressants and Stimulants: Efficacy of desipramine in depressed outpatients, response according to Research Diagnostic Criteria diagnoses and severity of illness (1983) (5)
- Interim analysis clarification. (1995) (5)
- Obsessive-Compulsive Disorder: Psychological and Pharmacological Treatment (1986) (5)
- Recent developments in the understanding and pharmacotherapy of panic attacks. (1986) (5)
- Pharmacological treatment of social phobia (2004) (5)
- Pharmacotherapy of social phobia. A condition distinct from panic attacks. (1987) (5)
- Medication therapy for social phobia. (1994) (5)
- Efficacy of desipramine in mildly depressed patients: a double-blind, placebo-controlled trial [proceedings]. (1981) (5)
- P-6-14 Long-term sertraline treatment of obsessive compulsive disorder: A 2 year study (1995) (4)
- Pharmacological Treatment for Social Anxiety Disorder (2014) (4)
- Dimensional versus categorical response to moclobemide in social phobia. (1998) (4)
- Psychopharmacology for Social Anxiety Disorder (2010) (4)
- Long-Term Follow-Up Study of Patients With Refractory Obsessive-Compulsive Disorder (2008) (4)
- Response of alcoholic and nonalcoholic panic patients to lactate infusion. (1990) (4)
- Results from a randomized, double-blind, multicenter trial of sertaline in the treatment of moderate-to-severe social phobia (social anxiety disorder) (2002) (4)
- Long-term sertraline treatment of obsessive compulsive disorder: a 52-week double-blind comparative study versus placebo (1992) (3)
- Insulin levels during lactate infusion. (1984) (3)
- Drug treatment of phobias. Efficacy and optimum use. (1987) (3)
- Dr. Marshall and Colleagues Reply (2000) (3)
- Panic disorder: Approaches of DSM-IV (1990) (3)
- Tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of panic disorder: brief review. (1989) (3)
- Randomized, Double-Blind Study of Fixed-Dose Intranasal Esketamine Plus Oral Antidepressant vs. Active Control in Treatment-Resistant Depression (2019) (2)
- Mania occurring during treatment for depersonalization: a report of two cases. (1980) (2)
- Psychiatric Aspects of Lyme Disease in Children and Adolescents: A Community Epidemiologic Study in Westchester, New York (1994) (2)
- Newer uses for older psychotropic medications. (1982) (2)
- The Cuban health care system; a study in the evaluation of health care systems (1969) (2)
- Prodromal symptoms in panic disorder. (2006) (2)
- Functional classification of anxiety‐panic (1993) (2)
- Borderline personality disorder and depression. (1992) (2)
- Psychopharmacological dissection of nonendogenous depression. (1984) (2)
- TAKING CHRONIC FATIGUE SYNDROME SERIOUSLY. REPLY (1992) (2)
- P.3.006 A double-blind, placebo-controlled trial ofvenlafaxine XR in the short-term treatment of panic disorder (2004) (2)
- Biological tests in the differential diagnosis of anxiety disorders (1990) (1)
- A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Desvenlafaxine Extended-Release Tablets in Generalized Social AnxietyDisorder (2015) (1)
- Neural circuits of anxiolytic and antidepressant pherine molecules (2020) (1)
- Social Phobia-Reply (1986) (1)
- Pharmacotherapy of Personality Disorders (1988) (1)
- Issues in the design of trials for the evaluation of psychopharmacological treatments for social phobia (1996) (1)
- Pharmacological treatment of social phobia: Traditional MAOIs and moclobemide (1993) (1)
- Case 1. Assessment and treatment of phobic anxiety. (1979) (1)
- Taking chronic fatigue syndrome seriously. (1992) (1)
- In Memoriam: Donald F Klein, MD. (2019) (1)
- Essential Evidence-Based Psychopharmacology: Evidence-based pharmacotherapy of social anxiety disorder (2012) (1)
- An expert panel review of clinical challenges in psychiatry AUGMENTATION STRATEGIES By (2012) (0)
- Drug Treatment of Phobias (1987) (0)
- Solid, orally administrable ribavirin dosage forms and methods for their preparation (1998) (0)
- Effects of fenfluramine on plasma homovanillic acid in healthy subjects (2005) (0)
- The Biology of Anxiety (1983) (0)
- COGNITIVE BEHAVIORAL GROUP THERAPY AND PHENELZINE BOTH EFFECTIVE IN SOCIALPHOBIA (1999) (0)
- EFFICACY OF FLUVOXAMINE IN OCD: A SECOND MULTICENTER STUDY (1992) (0)
- Behavioral and Neuroendocrine Responses to Oral m-Chlorophenylpiperazine and Fenfluramine in Patients and Healthy Volunteers (2016) (0)
- P.3.064 Efficacy of safety of venlafaxine XR and paroxetine in the short-term treatment of SAD (2003) (0)
- BRIEF REPORTS: Fluoxetine Treatment of Obsessive‐Compulsive Disorder An Open Clinical Trial (1989) (0)
- Psychobiological integration in obsessive-compulsive disorder (1988) (0)
- Controlled Study of Cognitive Deficits (2020) (0)
- Have you controlled for muscle tension and initiation of a panic attack as an explanation for increased lactate and pyruvate (1982) (0)
- What are serum calcium levels like during panic? What is the effect of intravenous calcium alone? (1982) (0)
- Reply to Franklin: Using Combination Treatments for OCD: A Reply to Franklin (2005) (0)
- The clinical use of hemodiaysis and peritoneal dialysis. (1966) (0)
- Tranylcypromine treatment of major depression. (1987) (0)
- Antidepressant-induced cycle acceleration in bipolar disorder. (1996) (0)
- Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements. (1991) (0)
- Erratum: Comparison of clomipramine, alprazolam, and placebo in the treatment of obsessive-compulsive disorder (Human Psychopharmacology, 7(6), 389-395, (1992)) (1993) (0)
- Review SOCIAL ANXIETY DISORDER IN DSM-5 (2017) (0)
- Are GABA (??-aminobutyric acid) agonists useful for treating panic disorders? (1982) (0)
- MAOIs in DST nonsuppressors. (1989) (0)
- Subject Index Vol. 12, 1984 (1984) (0)
- Efficacy of venlafaxine XR and placebo in social anxiety disorder: Effects of gender and physical symptoms (2007) (0)
- Hypnotizability and PTSD. (1988) (0)
- ["Nervous breakdown": a diagnostic characterization study]. (1997) (0)
- Anxiety Disorders: The emergence of social anxiety disorder as a major medical condition (2010) (0)
- On dysmorphophobia misdiagnosed as obsessive-compulsive disorder. (1990) (0)
- How does increased lactate actually cause panic (1982) (0)
- Treatment of depersonalization disorder with fluoxetine: a case report (2008) (0)
- Novel Therapeutic Indications of Antidepressant Drugs (1998) (0)
- Treatment of Atypical Depression: Phenelzine, Imipramine, and Placebo (1986) (0)
- Biochemical Effects and Antidepressant Mechanisms of L-Deprenyl (1984) (0)
- Copyright Informa UK Limited 2008 Not for Sale or Comercial Distribution (2008) (0)
- The place of drugs and cognitive behavior therapies in social phobia (1999) (0)
- Liebowitz Social Anxiety Scale for Children and Adolescents (2021) (0)
- Unresolved issues in the treatment of agoraphobia with panic attacks. (1982) (0)
- 47-3 Pharmacological treatment of social phobia: An overview (1997) (0)
- DSM-III-R anxiety classification: impact on psychopharmacology clinical trials. (1988) (0)
- Gaze Anxiety Rating Scale (2014) (0)
- Chapter 22 – Psychopharmacology for Social Anxiety Disorder (2014) (0)
- Patient's dramatic mood swings present challenge for therapist. (1983) (0)
- Preventable endemic cretinism. (1969) (0)
- Interim Analyses and Publication of Clinical Trials (1986) (0)
- Repeat M-CPP challenge during fluoxetine treatment in obsessive-compulsive disorder: Behavioral and neuroendocrine responses (1989) (0)
- Academic Highlights: Easing the Burden of Social Anxiety Disorder (2008) (0)
- BORDERLINE PERSONALITY DISORDER AND DEPRESSION. AUTHOR'S REPLY (1992) (0)
- Social Anxiety Disorder: Epidemiology, Diagnosis, and Comorbidities (2005) (0)
- Post‐traumatic stress disorder: what's in a name? (1997) (0)
- Integrating Neurobiology and Psychopathology into Evidence-Based Treatment of Social Anxiety Disorder (2005) (0)
- You said 31 of 42 patients panicked with lactate. Is there any difference between patients with and those without mitral valve prolapse (MVP) (1982) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Michael R. Liebowitz?
Michael R. Liebowitz is affiliated with the following schools:
